|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Irani J: Sunitinib versus interferon-alpha
in metastatic renal-cell carcinoma. Prog Urol. 17:9962007.In
French. View Article : Google Scholar
|
|
4
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lam JS, Leppert JT, Belldegrun AS and
Figlin RA: Novel approaches in the therapy of metastatic renal cell
carcinoma. World J Urol. 23:202–212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patton JG, Mayer SA, Tempst P and
Nadal-Ginard B: Characterization and molecular cloning of
polypyrimidine tract-binding protein: A component of a complex
necessary for pre-mRNA splicing. Genes Dev. 5:1237–1251. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Romanelli MG, Diani E and Lievens PM: New
insights into functional roles of the polypyrimidine tract-binding
protein. Int J Mol Sci. 14:22906–22932. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xue Y, Zhou Y, Wu T, Zhu T, Ji X, Kwon YS,
Zhang C, Yeo G, Black DL, Sun H, et al: Genome-wide analysis of
PTB-RNA interactions reveals a strategy used by the general
splicing repressor to modulate exon inclusion or skipping. Mol
Cell. 36:996–1006. 2009. View Article : Google Scholar
|
|
11
|
Llorian M, Schwartz S, Clark TA, Hollander
D, Tan LY, Spellman R, Gordon A, Schweitzer AC, de la Grange P, Ast
G, et al: Position-dependent alternative splicing activity revealed
by global profiling of alternative splicing events regulated by
PTB. Nat Struct Mol Biol. 17:1114–1123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McCutcheon IE, Hentschel SJ, Fuller GN,
Jin W and Cote GJ: Expression of the splicing regulator
polypyrimidine tract-binding protein in normal and neoplastic
brain. Neuro Oncol. 6:9–14. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheung HC, Hai T, Zhu W, Baggerly KA,
Tsavachidis S, Krahe R and Cote GJ: Splicing factors PTBP1 and
PTBP2 promote proliferation and migration of glioma cell lines.
Brain. 132:2277–2288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takahashi H, Nishimura J, Kagawa Y, Kano
Y, Takahashi Y, Wu X, Hiraki M, Hamabe A, Konno M, Haraguchi N, et
al: Significance of polypyrimidine tract-binding protein 1
expression in colorectal cancer. Mol Cancer Ther. 14:1705–1716.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He X, Pool M, Darcy KM, Lim SB, Auersperg
N, Coon JS and Beck WT: Knockdown of polypyrimidine tract-binding
protein suppresses ovarian tumor cell growth and invasiveness in
vitro. Oncogene. 26:4961–4968. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sugiyama T, Taniguchi K, Matsuhashi N,
Tajirika T, Futamura M, Takai T, Akao Y and Yoshida K: MiR-133b
inhibits growth of human gastric cancer cells by silencing pyruvate
kinase muscle-splicer polypyrimidine tract-binding protein 1.
Cancer Sci. 107:1767–1775. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He X, Arslan AD, Ho TT, Yuan C, Stampfer
MR and Beck WT: Involvement of polypyrimidine tract-binding protein
(PTBP1) in maintaining breast cancer cell growth and malignant
properties. Oncogenesis. 3:e842014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheung HC, Corley LJ, Fuller GN,
McCutcheon IE and Cote GJ: Polypyrimidine tract binding protein and
Notch1 are independently re-expressed in glioma. Mod Pathol.
19:1034–1041. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Christofk HR, Vander Heiden MG, Harris MH,
Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and
Cantley LC: The M2 splice isoform of pyruvate kinase is important
for cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
David CJ, Chen M, Assanah M, Canoll P and
Manley JL: HnRNP proteins controlled by c-Myc deregulate pyruvate
kinase mRNA splicing in cancer. Nature. 463:364–368. 2010.
View Article : Google Scholar :
|
|
21
|
Taniguchi K, Sugito N, Kumazaki M,
Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama
K, et al: MicroRNA-124 inhibits cancer cell growth through
PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett.
363:17–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang MJ and Lin S: A region within the
5′-untranslated region of hypoxia-inducible factor-1alpha mRNA
mediates its turnover in lung adenocarcinoma cells. J Biol Chem.
284:36500–36510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bielli P, Bordi M, Di Biasio V and Sette
C: Regulation of BCL-X splicing reveals a role for the
polypyrimidine tract binding protein (PTBP1/hnRNP I) in alternative
5′ splice site selection. Nucleic Acids Res. 42:12070–12081. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoon J and Herts BR: Staging renal cell
carcinoma with helical CT: The revised 1997 AJCC and UICC TNM
criteria. Crit Rev Computed Tomogr. 44:229–249. 2003. View Article : Google Scholar
|
|
25
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.In German. PubMed/NCBI
|
|
26
|
Li HL, Han L, Chen HR, Meng F, Liu QH, Pan
ZQ, Bai J and Zheng JN: PinX1 serves as a potential prognostic
indicator for clear cell renal cell carcinoma and inhibits its
invasion and metastasis by suppressing MMP-2 via NF-κB-dependent
transcription. Oncotarget. 6:21406–21420. 2015.PubMed/NCBI
|
|
27
|
Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y,
Zhao L, Zhang Y, Huang B and Lu J: LincRNA-ROR induces
epithelial-to-mesenchymal transition and contributes to breast
cancer tumorigenesis and metastasis. Cell Death Dis. 5:e12872014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thompson Coon J1, Hoyle M, Green C, Liu Z,
Welch K, Moxham T and Stein K: Bevacizumab, sorafenib tosylate,
sunitinib and temsirolimus for renal cell carcinoma: a systematic
review and economic evaluation. Health Technol Assess. 14:1–184.
iii–iv. 2010. View Article : Google Scholar
|
|
29
|
Kitamura H, Takahashi A, Takei F, Hotta H,
Miyao N, Shindo T, Igarashi M, Tachiki H, Kunishima Y, Muranaka T,
et al Sapporo Medical University Urologic Oncology Consortium:
Molecular-targeted therapy and surgery may prolong survival of
renal cell carcinoma patients with bone metastasis: A
multi-institutional retrospective study in Japan. Anticancer Res.
36:5531–5536. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Audenet F, Yates DR, Cancel-Tassin G,
Cussenot O and Rouprêt M: Genetic pathways involved in
carcinogenesis of clear cell renal cell carcinoma: Genomics towards
personalized medicine. BJU Int. 109:1864–1870. 2012. View Article : Google Scholar
|
|
31
|
Hynes RO: Metastatic potential: Generic
predisposition of the primary tumor or rare, metastatic variants-or
both? Cell. 113:821–823. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Semenza GL: Hypoxia-inducible factor 1
(HIF-1) pathway. Sci STKE. 2007:cm82007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ke Q and Costa M: Hypoxia-inducible
factor-1 (HIF-1). Mol Pharmacol. 70:1469–1480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen F, Fujinaga T, Shoji T, Miyahara R,
Bando T, Okubo K, Hirata T and Date H: Pulmonary resection for
metastasis from renal cell carcinoma. Interact Cardiovasc Thorac
Surg. 7:825–828. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al TARGET Study Group: Sorafenib in advanced clear-cell
renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
